Multiple sclerosis (MS) is a progressive T cell-mediated autoimmune demyelinating inflammatory disease of the central nervous system (CNS). Although it is recognized that cognitive deficits represent a manifestation of the disease, the underlying pathogenic mechanisms remain unknown. Here we provide evidence of spatial reference memory impairments during the pre-motor phase of experimental autoimmune encephalomyelitis (EAE) in mice. Specifically, these cognitive deficits were accompanied by downregulation of choline acetyltransferase (ChAT) mRNA expression on day 5 and 11 post-immunization, and up-regulation of inflammatory cytokines in the hippocampus and prefrontal cortex. Moreover, a marked increase in B 1 R mRNA expression occurred selectively in the hippocampus, whereas protein level was upregulated in both brain areas. Genetic deletion of kinin B 1 R attenuated cognitive deficits and cholinergic dysfunction, and blocked mRNA expression of both IL-17 and IFN-c in the prefrontal cortex, lymph node and spleen of mice subjected to EAE. The discovery of kinin receptors, mainly B 1 R, as a target for controlling neuroinflammatory response, as well as the cognitive deficits induced by EAE may foster the therapeutic exploitation of the kallikrein-kinin system (KKS), in particular for the treatment of autoimmune disorders, such as MS, mainly during pre-symptomatic phase.
Introduction
Multiple sclerosis (MS), a chronic inflammatory and demyelinating disease that affects the central nervous system (CNS) (Sospedra and Martin, 2005 ) is considered to be an autoimmune pathology in which autoaggressive Th1 and Th17 lymphocytes induce a response against components of myelin (Goverman, 2009; Sospedra and Martin, 2005; Steinman, 2007) . Th1 and Th17 cells are characterized by their expression of interferon-c (IFN-c) and interleukin-17 (IL-17), respectively. Experimental autoimmune encephalomyelitis (EAE), a CD4 + T cell-mediated disease of the CNS, is the best known animal model of MS and can be induced in susceptible rodents and other animals by immunization with myelin antigens such as myelin oligodendrocytes glycoprotein (MOG) (Steinman, 2007) . White matter inflammation, loss of myelin and consequent neuronal degeneration, the pathological hallmarks of MS and EAE, are thought to determine the disease severity (Ffrench-Constant, 1994) . Clinical symptoms in MS include a progressive decline in motor and sensory functions and permanent disability (Steinman, 2007) . Nonetheless, recent evidence has shown that, in MS, the neuronal compartment of the CNS is affected in parallel to, and even independently of, white matter damage, which has led to a reevaluation of the perceived relationship between inflammation and neurodegeneration in this disease (Centonze et al., 2010; Steinman, 2007) . Studies using magnetic resonance imaging (MRI) revealed that the gray matter atrophy, which occurs in cortical and deep sub-cortical brain regions (Filippi et al., 2003) , begins early in the disease, continues as the disease progresses (Lisak, 2007) and correlates with motor, sensory and visual disability (Magnano et al., 2006) . Moreover, there is few evidence indicating that about 50-70% of MS patients experience important cognitive deficits (Rao, 1995; Shi et al., 2008) which are detectable even before a definitive diagnosis of MS is made. These cognitive and emotional symptoms related to MS strongly affect patients' ability to work, as well as their quality of life (Engel et al., 2007) . Although the cause of mem-ory dysfunction in MS is currently unknown, information-processing speed and working memory are the most frequently detected cognitive deficits in MS (Rao et al., 1991) . In addition, verbal and spatial learning are also affected, reflecting hippocampal dysfunction, especially atrophy of the CA1 region (Sicotte et al., 2008) . In this regard, some reports have proposed a linkage between cholinergic system, neuroinflammation and cognitive impairments (Field et al., 2012; Ruan et al., 2010; Ullrich et al., 2010) . Particularly, impairment within the cholinergic system has been demonstrated in MS (Antonelli et al., 2013) . For instance, Kooi et al. (2011) reported that in MS hippocampus, both activity and protein expression of choline acetyltransferase (ChAT), the acetylcholine synthesizing enzyme, were decreased, whereas the activity and protein expression of acetylcholinesterase (AChE), the acetylcholine degrading enzyme, were found to be unaltered (Kooi et al., 2011) . Moreover, cholinergic projections arise from basal forebrain nuclei such as medial septum/vertical limb of the diagonal band to the hippocampus and from nucleus basalis (of Meynert) to the cortex (Wevers, 2011) . This anatomical split of the cholinergic system into neocortical and hippocampal divisions underlies cholinergic modulation of working (Croxson et al., 2011) and spatial-reference memories (Deiana et al., 2011) , respectively.
The identification of the specific cognitive deficits observed before motor symptoms in MS is of high interest because they may be useful as temporal markers of the disease, and for testing of potential therapeutic treatments even before the onset of motor impairments. Moreover, drugs currently used to treat MS focus mainly on the control of autoimmune and neuroinflammatory responses. Hence, it is incumbent upon novel studies to elucidate a molecular substrate, with the view of discovering therapeutic interventions. In this context, we and others have previously demonstrated that kinin receptors, mainly the B 1 receptor (B 1 R), exert a critical role in regulating the early development of experimental autoimmune encephalomyelitis (EAE) progression by modulating the onset of the immune response and affecting the functioning of astrocytes/ microglia cells (Dutra et al., 2011) .
Kinins (such as bradykinin and kallidin) are the most potent autacoids involved in inflammatory, vascular and pain processes, and constitute the end-products of the so-called kallikrein-kinin system (KKS). Kinins exert most of their biological effects by the activation of two G-protein coupled receptors, denoted B 1 and B 2 receptors Marceau and Regoli, 2004) . In this regard, Wang and Wang demonstrated that injection of bradykinin (BK), a preferential B 2 R agonist, is able to induce learning and memory impairment when administered into the rat hippocampus (Wang and Wang, 2002) . Extending this idea, Prediger et al. (2008) showed that kinins, acting via activation of B 1 R and B 2 R in the CNS, exert a critical role in the spatial learning and memory deficits induced by the b-amyloid peptide (Ab) in mice (Prediger et al., 2008) . In addition, up-regulation of both kinin receptors in the brain was related, directly or indirectly, to cognitive processes after infusion of Ab (Viel et al., 2008) . On the other hand, the linkage between KKS and the cholinergic system is currently not fully established. A relevant study conducted by Buccafusco and Serra (1985) showed that the intracerebroventricular (i.c.v.) injection of BK in conscious, freely moving rats evoked dose-related increases in arterial pressure, and pretreatment with hemicholinium-3, which deplete brain acetylcholine levels, produced a choline-reversible blockade of the cardiovascular response to BK (Buccafusco and Serra, 1985) . This notion has been extended further by Barnes et al. (1998) , who demonstrated that BK-induced bronchoconstrictor response in asthmatics is dependent of cholinergic and sensory nerves (Barnes et al., 1998) . However, no consistent evidence for the linkage between KKS and the cholinergic system during neuroinflammatory response, such as MS, has to date been documented.
Because kinin receptors are reported to be involved in the etiology of EAE (Dutra et al., 2011; Gobel et al., 2011; Schulze-Topphoff et al., 2009) , and also directly modulate cognitive impairments in experimental models of neurodegenerative disease, such as Alzheimer's disease (Prediger et al., 2008) , and some kinin-induced effects depends of cholinergic and sensory nerve stimulation (Abraham et al., 2006) , herein we hypothesize that the KKS may play a key role in modulating the development of cognitive impairments in MS by decreasing neuroinflammation and mitigating cholinergic system dysfunction.
Materials and methods

Experimental animals
Experiments were conducted using female C57BL/6 wild-type,
) and kinin B 1 B 2 R-knockout (B 1 B 2 R À/À ) mice (6-10 weeks old). Deletion of the entire coding sequences of the kinin receptors was achieved according to previously described methods (Dutra et al., 2011; Pesquero et al., 2000) .
-and B 1 B 2 R À/À -deficient mice on the 129/SvJ background were backcrossed to C57BL/6 to produce F 10 offspring. Following the F 10 offspring the line is 99% genetically identical to the recipient strain (C57BL/6) and is considered congenic with it; therefore we maintained this linage by crossing them with each other. The C57BL/6 animals were used as controls. The mice were kept in groups of six to nine animals per cage, maintained under controlled temperature (22 ± 1°C), with a 12 h light/dark cycle (lights on at 7:00 a.m.) and were given free access to food and water. All procedures used in the present study followed the Guide for the Care and Use of Laboratory Animals and were approved by the Animal Ethics Committee of the Universidade Federal de Santa Catarina (CEUA-UFSC, protocol number 23080038266/2008-43).
EAE induction
Experimental autoimmune encephalomyelitis (EAE) was induced by subcutaneous (s.c.) immunization into the flanks with 200 ll of an emulsion containing 200 lg MOG 35-55 peptide and 500 lg Mycobacterium tuberculosis extract H37Ra in incomplete Freund's adjuvant oil, as previously described (Stromnes and Goverman, 2006) . In addition, the animals received 300 ng of Pertussis toxin intraperitoneally (i.p.) on day 0 and day 2 post-immunization. The animals were monitored daily and neurological impairment was quantified using a clinical scale after day 1 postimmunization (Stromnes and Goverman, 2006) : 0, no signs of disease; 1, loss of tone in the tail; 2, hindlimb paresis; 3, hindlimb paralysis; 4, tetraplegia and 5, moribund and/or death.
Behavioral tests
Rotarod test
In order to evaluate motor coordination, the mice were placed on a rotarod apparatus at a fixed rotational speed of 4 rpm, as previously described (Dutra et al., 2011) (Fig. 1A) . The maximum time for each trial was set at 60 s. Rotarod training was performed prior to disease induction and consisted of three consecutive trials in which the animals became familiar with the task. After disease induction, the mice were repeatedly tested at different time points until day 25 post-immunization.
Object location task
After seven days of disease induction, the spatial memory of mice was assessed using the object location task (Fig. 1A) . The task is based on the spontaneous tendency of rodents, previously exposed to two identical objects, to later explore one of the objects -replaced in a novel location -for a longer time than they explore the non-displaced object (Assini et al., 2009) , and has been used for the evaluation of hippocampal-dependent memories (Assini et al., 2009) . The experimental apparatus used in this study was an openfield box (50 cm wide Â 50 cm deep Â 40 cm high) made of transparent PVC, placed in a dimly lit (7 lx) and sound-isolated room. Identical plastic rectangles (4 cm high Â 4.5 cm wide) were used as objects. The mice were placed in the center of the apparatus with two identical objects for 5 min. The objects were placed 7 cm away from the walls of the open field. Exploration of the objects was recorded using a stopwatch when mice sniffed, whisked, or looked at the objects from no more than 1 cm away. After the training phase, the mice were removed from the apparatus for 90 min. After this inter-trial interval, one object was moved to a new location. The time spent by the animals exploring the objects in new (novel) and old (familiar) locations was recorded over 5 min. All locations of the objects were counterbalanced among the groups. In order to analyze the cognitive performance, a location index was calculated as previously described (Assini et al., 2009) : (Tnovel Â 100)/(Tnovel + Tfamiliar), where Tnovel is the time spent exploring the displaced object and Tfamiliar is the time spent exploring the non-displaced object. , novel object location memory (E and F) and Morris water maze (G and H) were analyzed in control and EAE group. Motor coordination was evaluated using the rotarod apparatus over 25 days post-immunization (p.i.). Neurological severity scale scoring was performed nine days after EAE induction; a higher score indicates greater neurological impairment up to a maximum of 10 points. The object location test was performed seven days after immunization and the location index (%) assessed 90 min after training sessions in mice with or without EAE. The results of water maze test are expressed as latency to find the hidden platform during the four training trials (G) or as a delta value for Trial 1 -Trial 2 (H). Data are presented as means ± SEM (B, C, E, F, G and H) or medians ± interquartile range (D) of 6-9 mice per group and are representative of three independent experiments. ⁄ p < 0.05 versus random chance (50% of displaced object investigations in test trial), and ⁄⁄ p < 0.001 versus control group (Student's t-test -B, C and F; and repeated measures ANOVA -G).
Water maze task
The apparatus was made of black painted fiberglass (97 Â 60 Â 60 cm), and the water was maintained at 23 ± 2°C. Four distant cues (55 Â 55 cm) were placed 30 cm above the upper edge of the water tank. The target platform (10 Â 10 cm), made of transparent acrylic resin was submerged 1-1.5 cm beneath the water surface. Starting points were marked on the outside of the pool as north (N), south (S), east (E), and west (W). These were positioned with the lower edge 30 cm above the upper edge of the water tank, and the position of a symbol marked the midpoint on the perimeter of a quadrant (circle = NE quadrant, square = SE quadrant, cross = SW quadrant, and diamond = NW quadrant). If a mouse did not find the platform during the trial period of 60 s, it was gently guided to it. The water maze test was evaluated from 8-11 days after disease induction, and the animals were submitted to a working memory version of the water maze using a protocol identical to that previously described (Moreira et al., 2012) . There is compelling evidence that the prefrontal cortex plays a critical role in this kind of memory (Faw, 2003) . Specifically, we used a protocol that consists of four training days (four trials per day), during which the animals were placed in the tank facing the wall and were then allowed to swim freely to the submerged platform. The initial position in which the animal was placed in the tank was one of the four vertices of the imaginary quadrants of the tank, and this was varied among trials in a pseudo-random way. The animal was allowed to remain on the platform for 30 s and was then moved to the next initial position without leaving the tank. This procedure was used to ensure that the animals maintained the visuospatial information of the maze that was available during execution of the working memory task. On each subsequent training day, the platform position was moved to the center of another quadrant of the tank in a pseudo-random way. The experiments were videotaped and the scores for latency of escape from the starting point to the platform and swimming speed were later measured through the ANY-maze™ video tracking system (Stoelting Co., Wood Dale IL, USA).
Neurological severity score
After nine days of disease induction, mice were rated on the 10-point neurological severity scale (NSS) (Fig. 1A) , a composite behavioral scale designed to measure the general neurological state, as previously described (Schwarzbold et al., 2010) . The mice were assessed for the following traits: presence of paresis; inability to walk straight; impairment of seeking behavior; absence of a perceptible startle reflex; inability to exit a 30-cm-diameter circle; inability to walk on 3-, 2-, and 1-cm-wide beams; and inability to balance on a 0.7-cm-wide beam and a 0.5-cm-diameter round beam for at least 10 s. If a mouse showed impairment in one of these traits, a value of 1 was added to its NSS score. Higher scores on the NSS thus indicate greater neurological impairment.
RNA extraction and real-time quantitative PCR
Total RNA from the hippocampus and prefrontal cortex (11 days post-immunization, Fig. 1A ) was extracted using the Trizol protocol and concentrations were determined using a NanoDrop 1100 (NanoDrop Technologies, Wilmington, DE, USA). An amount of 100 ng of total RNA was used for cDNA synthesis. Reverse transcription was performed as described in the M-MLV Reverse Transcriptase protocol according to the manufacturer's instructions. cDNA was amplified in duplicate using the TaqMan Ò Universal PCR Master Mix Kit with specific TaqMan Gene Expression target genes, the 3 0 quencher MGB and FAM-labeled probes for mouse choline acetyltransferase (ChAT, Mm01221887_m1) and acetylcholinesterase (AChE, Mm00477275_m1), interleukin-17 (IL-17, Mm00439618_m1), interferon-gamma (IFN-c, Mm99999071_m1), kinin B 1 R (Mm00432059_s1) and kinin B 2 R (Mm01339907_m1). GAPDH (NM_008084.2) was used as an endogenous control for normalization. The PCR reactions were performed in a 96-well Optical Reaction Plate (Applied Biosystems, Foster City, CA, USA). The thermocycler parameters were as follows: 50°C for 2 min, 95°C for 10 min, 50 cycles of 95°C for 15 s and 60°C for 1 min. Expression of the target genes was calibrated against conditions found in control animals or cells (i.e. naïve or wild-type (WT) mice).
Western blot analysis
The hippocampus and prefrontal cortex tissues were collected five days after EAE induction and homogenized in complete radio immunoprecipitation lysis buffer (RIPA). Equal amounts of protein for each sample (30 lg) were loaded per lane and electrophoretically separated using 10% denaturing polyacrylamide gel electrophoresis (SDS-PAGE). After that, the proteins were transferred to nitrocellulose membranes using a Mini Trans-Blot Cell System (Bio-Rad Laboratories Inc., Hercules, CA, USA). Western blot analysis was carried out using polyclonal rabbit anti-B 1 R (1:1000) (Alomone Labs, Jerusalem, Israel) incubated overnight. After washing, membrane was incubated with secondary antibodies conjugated to horseradish peroxidase (1:25,000, Cell Signaling Technology, Danvers, MA, USA). The immunocomplexes were visualized using SuperSignal West Femto Chemiluminescent Substrate detection system (Thermo Fischer Scientific, Rockford, IL, USA) and densitometric values were normalized using monoclonal mouse b-actin antibody (1:500, Cell Signaling Technology, Danvers, MA, USA).
Drugs and reagents
Pertussis toxin, phosphate buffered saline (PBS) and incomplete Freund's adjuvant oil were all purchased from Sigma Chemical Co. (St. Louis, MO, USA). The MOG 35-55 peptide (MEVGWYRSPFSRVVH-LYRNGK) was obtained from EZBiolab (Carmel, IN, USA) and the M. tuberculosis extract H37Ra from Difco Laboratories (Detroit, MI, USA). The primers and probes for mouse ChAT, AChE, IL-17, IFNc, B 1 R, B 2 R and GAPDH were purchased from Applied Biosystems (Warrington, UK). The polyclonal rabbit anti-B 1 R was purchased from Alomone Labs (Jerusalem, Israel). Other reagents used were all of analytical grade and obtained from different commercial sources.
Statistical analysis
Data are presented as means ± SEM. The object location task was analyzed by one-sample t-test to determine whether the location index was different from random chance (50%). Other statistical analyses were carried out by using a Student's t-test or by oneway analysis of variance (ANOVA), with repeated measures when appropriate. Following significant ANOVAs, multiple post-hoc comparisons were performed using Bonferroni or Newman-Keuls tests, depending on the experimental protocol. p-Values of less than 0.05 (p < 0.05) were considered significant. The statistical analyses were performed using GraphPad Prism 4 software (GraphPad Software Inc., San Diego, CA, USA).
Results
Cognitive deficits associated with cholinergic dysfunction precede motor impairments in EAE
As previously described (Dutra et al., 2011 ), C57BL/6 mice immunized with MOG 35-55 antigen developed EAE starting 13 days following immunization, and the clinical severity increased to maximum by day 20 (Fig. 1B and C) . However, recent report showed that 50-70% of MS patients have some cognitive deficits during the course of the disease (Rao, 1995; Rao et al., 1991; Shi et al., 2008) . Thus, here we assessed whether learning and memory impairments could onset during the pre-motor phase of EAE (days 0-11 post-immunization, Fig. 1A ). Firstly, we evaluated short-term spatial memory of mice using an object location task. One week after EAE induction, object location memory performance was significantly impaired, as no difference between the time spent exploring displaced and non-displaced objects could be observed (t = 1.43; p = 0.20; Fig. 1F ). In contrast, the control group, treated with saline one week before behavioral testing, explored the object replaced in a novel location for a longer time than the non-displaced object, as indicated by a significant increase in location index in comparison to random chance (t = 9.88; p < 0.0005; Fig. 1F ). It should be noted that no innate preference for object position was exhibited in either control (t = 0.64; p = 0.55) or EAE (t = 0.38; p = 0.38) mice, as indicated by the similar amounts of time spent sniffing both objects during the 5-min familiarization (training) session (Fig. 1E) . Moreover, at this time, the animals (regardless of group) did not present any gross motor alterations, as assessed by rotarod test (Fig. 1B) , clinical score (Fig. 1C ) and neurological severity scores (Fig. 1D) .
Next, we assessed the spatial working and reference memory of mice over days 8-11 post-immunization using the water maze task. The performance of the EAE-group in the water maze test was significantly impaired compared with control animals, as illustrated by the mean latency to escape to the hidden platform (Fig. 1G) . The latency to escape to the hidden platform decreased over the training trials for both groups (main effect of repetition, F(3, 174) = 11.19, p < 0.00005), however, treatment differences were observed (main effect of EAE, F(1, 58) = 13.32, p < 0.0005). Specifically, escape latencies significantly differed across treatments on training trials 3 and 4 (p < 0.05; Fig. 1G ), indicating spatial reference memory impairments. Moreover, we calculated a delta value by subtracting the value for trial one from trial two, as an index of working memory. As showed in Fig. 1H we observed no differences between groups (p = 0.86), indicating that EAE immunization did not disrupted working memory of mice. It is worth mentioning that the learning and memory deficits were independent from motor deficits as mice from each group had similar swimming speeds (data not shown).
There is extensive literature indicating that specific neural structures such as the hippocampus and prefrontal cortex plays a critical roles in different types of memory such as spatial reference (Burgess et al., 2002) and working memory (Faw, 2003; Wang et al., 2011) , respectively. Moreover, the close relationship between the disruption of the cholinergic system and cognitive deficits, such as working (Croxson et al., 2011) and spatial reference memories impairments (Deiana et al., 2011 ) is well established (Van Beek and Claassen, 2011) . Herein, in order to evaluate the possible molecular mechanisms underlying cognitive deficits induced by EAE model, we next investigate whether the spatial reference memory impairments were also linked to downregulation of cholinergic basal forebrain system. Thus, we measured ChAT mRNA expression in the hippocampus and prefrontal cortex during the motor pre-symptomatic phase of EAE. At 11 days post-immunization, the expression of ChAT mRNA was markedly reduced in the hippocampus ( Fig. 2A ) and prefrontal cortex (Fig. 2B) of EAE mice, which might be the underlying cause of the spatial reference deficits. Accordingly to previous reports (Tu Fig. 2 . EAE-induced spatial reference memory deficits associated with cholinergic regulation during the pre-motor phase of disease. Animals were immunized with MOG peptide/CFA and Pertussis toxin. On days 5 and 11 post-immunization, total RNA was extracted from the hippocampus and prefrontal cortex of non-immunized (control) and EAE groups and processed for choline acetyltransferase (ChAT) (A, B, E and F) and acetylcholinesterase (AChE) (C and D), respectively. GAPDH mRNA was used to normalize the relative amounts of mRNA. Data are presented as means ± SEM of 6-9 mice per group and are representative of two independent experiments.
⁄⁄ p < 0.001 versus nonimmunized control group (Student's t-test).
et al., 2009), the expression of AChE mRNA (the key enzyme responsible for acetylcholine degradation) remained unaltered in the hippocampus and prefrontal cortex after EAE induction ( Fig. 2C and D) . In another set of experiments, we investigated whether ChAT mRNA is down-regulated in the hippocampus and prefrontal cortex in the earlier phase of EAE. Interestingly, on the 5th day after EAE, the expression of ChAT mRNA was significantly reduced in the hippocampus (Fig. 2E ) and prefrontal cortex (Fig. 2F) , when compared to the control group, suggesting that cholinergic down-regulation occur in the CNS before memory deficits.
B 1 R is over-expressed in the hippocampus during the pre-motor phase of EAE
Recent evidence points to the involvement of the KKS in MS and EAE models (Dos Santos et al., 2008; Dutra et al., 2011; Gobel et al., 2011; Schulze-Topphoff et al., 2009 ). Thus, we next investigate whether the spatial reference memory impairments seen here were also linked to the up-regulation of kinin B 1 and B 2 receptors in specific brain areas during the motor pre-symptomatic phase of EAE (on day 11 post-immunization). Basal expression of B 1 R (Fig. 3A and B) and B 2 R (Fig. 3C and D) were detected in the hippocampus and prefrontal cortex of non-immunized mice. On the other hand, during pre-motor phase of EAE, levels of kinin B 1 R transcript were increased a hundred-fold in the hippocampus (Fig. 3A) , but not in the prefrontal cortex (Fig. 3B) . Moreover, no significant difference in kinin B 2 R mRNA levels was observed between non-immunized and EAE-groups in the hippocampus and prefrontal cortex, respectively ( Fig. 3C and D) . Next, we investigated whether B 1 R protein levels was up-regulated before spatial reference memory impairments induced by EAE. As shown in Fig. 3 , only low protein levels of B 1 R were detected in the nonimmunized mouse hippocampus (Fig. 3E ) and prefrontal cortex (Fig. 3F ) tissues, respectively, but these values were markedly increased in EAE-group at 5 days post-immunization, suggesting that KKS may contribute to the appearance of cognitive deficits induced by EAE during pre-motor phase.
Genetic deletion of kinin B 1 R prevents cognitive impairments and cholinergic dysfunction in EAE
Accordingly, the genetic deletion of B 1 R (Fig. 4A ) drastically reduced the clinical score of EAE and blocked the development of the disease (Fig. 4B and C) . In marked contrast, for the genetic deletion of B 2 R, or in mice that lack the genes encoding both kinin B 1 R and B 2 R (B 1 B 2 R À/À ) no differences were found when compared to the wild-type EAE-group (Fig. 4B and C) . This indicates that B 1 R has a dominant role in influencing the development of the disease, as previously demonstrated (Dutra et al., 2011) . Presently, there is evidence indicating that kinin receptors exert a critical role in Fig. 3 . EAE-induced up-regulation of B 1 R mRNA and protein levels in the hippocampus and prefrontal cortex during the pre-motor phase of disease. Animals were immunized with MOG 35-55 peptide/CFA and Pertussis toxin. On days 5 and 11 post-immunization, total mRNA was extracted from the hippocampus and prefrontal cortex of nonimmunized (control) and EAE groups. The mRNA levels of B 1 R (A and B) and B 2 R (C and D) were measured by RT-PCR, on day 11 post-EAE induction. The housekeeping gene GAPDH mRNA was used to normalize the relative amounts of mRNA. The protein expression levels of B 1 R (E and F), in the hippocampus and prefrontal cortex, was determined by Western blot analysis on day 5 post-immunization. The level of protein was expressed as ratio of signal intensity for the target protein relative to that for b-actin, and their values was considered arbitrary units that represented the relative values among all samples. Data are presented as means ± SEM of 6-9 mice per group and are representative of two independent experiments. # p < 0.05 and ⁄⁄ p < 0.001 versus non-immunized control group (Student's t-test).
the spatial learning and memory deficits observed with aging and in experimental models of Alzheimer's disease (Lemos et al., 2010; Prediger et al., 2008; Wang and Wang, 2002) . Thus, in another set of experiments, we investigated whether the genetic deletion of kinin receptors could prevent the spatial reference memory deficits induced by EAE in mice. In previous studies, we performed adequate inter-strain comparisons between wild-type and B 1 R À/À , B 2 R À/À and B 1 B 2 R À/À mice, and these findings indicated that the genetic deletion of both B 1 R and B 2 R did not significantly disrupt spatial learning and memory processes in mice evaluated in the water maze task (Prediger et al., 2008 ). Herein we showed that genetic deletion of B 1 R significantly mitigated the spatial reference memory deficits of EAE mice in the water maze task, since the escape latencies significantly differed when compared with C57BL/6 EAE-induced group on training trials 3 and 4 (p < 0.05; Fig. 4D ). On the other hand, genetic deletion of B 2 R alone or both B 1 R and B 2 R (B 1 B 2 R À/À ) did not significantly prevent the cognitive impairments induced by EAE in mice (Fig. 4D) . Moreover, one-way ANO-VA indicated no differences between groups regarding the delta value of Trial 1 -Trial 2 (F(4, 130) = 0,85, p = 0,49; Fig. 4E ), reinforcing the suggestion of the absence of working memory alterations.
We next investigated whether B 1 R could modulate spatial reference memory by affecting the expression levels of ChAT mRNA in the hippocampus and prefrontal cortex during the pre-motor phase of EAE. As mentioned previously, in the EAE-group, a significant decrease in the expression of ChAT mRNA was observed in the hippocampus (Fig. 5A ) and prefrontal cortex (Fig. 5B) . Notably, in B 1 R À/À mice the down-regulation of ChAT was completely abolished in the hippocampus and prefrontal cortex of mice during premotor phase of EAE, respectively ( Fig. 5A and B) . However, the genetic deletion of B 2 R failed to inhibit the decrease in ChAT mRNA in the hippocampus (Fig. 5A ) and prefrontal cortex (Fig. 5B) after EAE induction. Moreover, in B 1 B 2 R À/À mice this effect was only observed in the hippocampus (Fig. 5A) . Once again, the levels of AChE mRNA in the hippocampus (Fig. 5C ) and prefrontal cortex (Fig. 5D ) remained unchanged after EAE induction in all groups.
3.4. Genetic deletion of B 1 R decreases the inflammatory response in the cerebral and peripheral tissues during the pre-motor phase of EAE Earlier studies have shown that autoaggressive Th17 and Th1 cells, directed against antigens that are derived from the CNS, can induce tissue damage and neuroinflammation, and thus have a crucial role during MS development (Moldovan et al., 2003; Stromnes et al., 2008; Tzartos et al., 2008) . It is now well-established that different proinflammatory mediators are produced both by infiltrating immune cells and by CNS-resident glial cells, mainly astrocytes and microglial cells, orchestrating a pathogenic cascade leading to neuroinflammation and axonal damage during MS (Gerard and Rollins, 2001; Ibrahim et al., 2001; Lock et al., 2002) . We therefore investigated whether B 1 R could modulate spatial reference memory by affecting CNS inflammation during the pre-motor phase of EAE. In the EAE-group, significant increases in the expression of IL-17 ( Fig. 6A and C) and IFN-c ( Fig. 6B and D) mRNAs were observed in the hippocampus and prefrontal cortex, respectively. Surprisingly, in both B 1 R À/À and B 1 B 2 R À/À mice, the up-regulation of IL-17 (Fig. 6C) and IFN-c (Fig. 6D ) was completely abolished in the cerebral prefrontal cortex at 11 days post-immunization, but this effect was not observed in the hippocampus (Fig. 6A and B) .
Furthermore, the deletion of B 2 R did not give rise to significant decreases in IL-17 and IFN-c expression in either the hippocampus or prefrontal cortex when assessed during pre-symptomatic phase of EAE (Fig. 6A-D) . In another set of experiments, we investigated whether IL-17 and IFN-c mRNA are up-regulated in the peripheral lymphoid tissue, such as lymph node and spleen, after EAE induction. As shown in Fig. 6(E-H) , in EAE-group, a significant up-regulation of IL-17 (Fig. 6E and G) and IFN-c (Fig. 6F and H ) mRNAs was observed in the lymph node and spleen, respectively. Of great relevance, genetic deletion of B 1 R resulted in a marked reduction of IL-17 and IFN-c mRNA in the lymph node (Fig. 6E and F) and spleen ( Fig. 6G and H) , respectively, at 11 days post-immunization, suggesting that B 1 R modulates inflammatory response in the cerebral and peripheral tissues during the pre-motor phase of EAE.
Discussion
Recent evidence has shown that the neuronal compartment of the CNS is affected in parallel to, and even independently of, white matter damage in MS (Centonze et al., 2010; Steinman, 2001) . Accordingly, cognitive impairment occurs in up to 65% of people with MS (Rao, 1995; Rao et al., 1991; Shi et al., 2008) . Although there is evidence that memory impairment among MS subjects are a consequence of inadequate initial learning and not a function of impaired retrieval (DeLuca et al., 1994) , the majority studies report that most patients have some difficulty in remembering information learned in the past (Beatty et al., 1996; Brissart et al., 2012) . For instance, verbal episodic memory impairment is frequent in patients with MS (Brissart et al., 2012; Rao et al., 1991) . Episodic memory refers to the conscious recollection of a unique past experience in terms of ''what'' happened, ''where'' and ''when'' it happened (Tulving, 1983 (Tulving, , 2007 . In this regard, herein we showed an impaired object location memory in the EAE-induced group. The object location task allows to measure the memory for locations, where objects were initially explored, by presenting two equal and familiar objects (''what'') during the test trial, with one of Fig. 5 . Kinin B 1 R deletion blocked ChAT mRNA levels down-regulation in the hippocampus and prefrontal cortex during the pre-motor phase of EAE. At the end of the 11th day, brain tissues were collected and processed for choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) mRNA expression. Total RNA was extracted from the hippocampus and prefrontal cortexes of mice in the C57BL/6 non-immunized group, the EAE group, and B 1 R À/À , B 2 R À/À and B 1 B 2 R À/À mice on day 11 p.i. The mRNA levels of
ChAT (A and B) and AChE (C and D) were measured in the hippocampus and prefrontal cortex, respectively. GAPDH mRNA was used to normalize the relative amounts of mRNA. The data are presented as means ± SEM of 6-9 mice/group and are representative of two independent experiments. # p < 0.05 and ## p < 0.001 versus wild-type naïve group and ⁄ p < 0.05 versus EAE-control group (one-way ANOVA with Newman-Keuls post hoc test).
the objects shifted to a novel location (''where''). Although two components of an episode experienced by animals were assessed conjointly, it is worth mentioning that it does not make up an episodic memory test (Ennaceur, 2010) , nevertheless, at least in part, we corroborated clinical data linking episodic memory impairment with MS. Afterwards, we showed that the performance of the EAEgroup in the Water maze task was significantly impaired when compared with control mice. Morris water maze performance involves different components, including concept formation (learning the general rules of the task), attention, working memory, and reference memory (Anisman and McIntyre, 2002) . Our experimental protocol allowed distinguishing between working and reference memories. In this regard, we presented evidence for specific reference memory impairments in the EAE group. Particularly, verbal and spatial learning are affected in MS subjects, reflecting hippocampal dysfunction (Sicotte et al., 2008) . Accumulated evidence now suggests that in EAE and MS pathology, T cell activation in the periphery against myelin antigens, and their subsequent invasion of the CNS, are considered as the primum movens of both the experimental and human diseases (Sospedra and Martin, 2005) . These T cells are capable of (1) producing inflammatory cytokines that may lead to differentiation into Th1 (IFN-c and TNF-a) or Th17 cells (McFarland and Martin, 2007) , and (2) up-regulating integrins such as VLA-4, that have the ability to enter the subarachnoid space by crossing the blood-cerebrospinal fluid (CSF) barrier in either the choroid plexus or the meningeal venules (Goverman, 2009; Steinman, 2007) . Through the permeabilized BBB, and attracted by chemokine release, other immune cells including CD8 + T cells, B cells and monocytes/macrophages migrate into the CNS (Fletcher et al., 2010) . Moreover, inside the CNS, the T cells are re-activated by MHC class II-expressing macrophage/microglia and dendritic cells (DCs), such as astrocytes, which express myelin epitopes (Goverman, 2009) . Despite the low abundance of DCs in these compartments, experiments that limited MHC class II expression to DCs showed that these cells were sufficient to support the development of EAE (Greter et al., 2005) , and that myeloid DCs within the CNS activated naïve myelin-specific T cells, which were recruited to the inflamed tissue, and facilitated their differentiation into Th17 cells (Bailey et al., 2007) . In this context, several lines of evidence suggest that T-cell CNS invasion might be considered as the first step in the chain of events leading to brain inflammation and the secondary neurodegeneration that occurs in MS patients (Centonze et al., 2010; Steinman, 2007) . However, only a limited number of studies have been devoted to understanding the precise mechanisms underlying the onset of cognitive deficits in this scenario. Here, we demonstrated that not only the white matter, but also gray matter structures such as the hippocampus and prefrontal cortex, are infiltrated by autoaggressive Th17 and Th1 cells during the early phase of EAE. In agreement with our data, it was recently found that inflammatory infiltrates in the striatum and the cortex are mainly composed of CD3 + T cells during the pre-symptomatic and symptomatic phases of EAE (Centonze et al., 2010; Steinman, 2007) . Moreover, a relevant study demonstrated learning and memory deficits following recovery from motor symptoms (90 days post-immunization) which were associated with decreases in ChAT activity and nerve growth factor (NGF) mRNA levels in the supraspinal structures (D'Intino et al., 2005) . This has been extended by Sicotte et al. (2008) , who demonstrated that MS patients and EAE mice showed hippocampal neurodegeneration, selective decrease in CA1 volume and loss of GABA-ergic interneurons. Nonetheless, these cognitive deficits were evaluated at a later stage of the disease. Moreover, the relationship between the cholinergic system and cognitive impairments is well established (Field et al., 2012; Ruan et al., 2010; Ullrich et al., 2010) . For instance, modulation of prefrontal and hippocampal function by forebrain cholinergic systems plays a critical role in the performance of spatial memory tasks in rodents, since both the prefrontal cortex and hippocampus receive substantial innervation from cholinergic cell bodies located in the basal forebrain. Indeed, loss of such cholinergic neurons has been correlated with memory deficits in a number of neurodegen- erative and inflammatory disorders (Mufson et al., 2002; Pizzo et al., 2002) . Our data confirm and largely extend these previous data, by demonstrating that EAE induces spatial reference memory impairments during the pre-symptomatic phase of disease, and that this is associated with ChAT down-regulation in the hippocampus and prefrontal cortex. In subsequent phases, autoaggressive T cells enter the parenchyma and, together with activated macrophage/microglial cells and astrocytes, over-express pro-inflammatory cytokines and nitric oxide (NO) that trigger demyelination, consequently activating neighboring immune or neural cells, and attracting further inflammatory cells into the CNS (Goverman, 2009) . Emerging evidence suggests that neuroinflammation could be regulated by neuropeptides, such as kinins (Dutra et al., 2011; Prediger et al., 2008; Schulze-Topphoff et al., 2009 ). In fact, there are, so far, several reasons for pointing B 1 R kinin as a potential therapeutic approach for the management of inflammatory diseases, such as MS. Initially, the induction of B 1 R has been associated with the production of proinflammatory mediators, stimulation of inflammatory cells, and, finally, activation of several intracellular signaling pathways . Moreover, high levels of kinin components, namely des-Arg 9 -bradykinin (DABK, selective agonist for B 1 R), bradykinin, kallikrein-1, kallikrein-6 and low-molecular-weight kininogens (KNGL), have been found in CNS tissue and cerebrospinal fluid from MS patients (Schulze-Topphoff et al., 2009 ). In addition, the B 1 R has been found to be up-regulated not only in brain endothelial cells (Prat et al., 2000) , but also in the peripheral T lymphocytes (Prat et al., 2005) of these patients. More recently, our group and others have reported that B 1 R exert a critical role in regulating the development and progression of EAE, as well as is up-regulate in MS patients (Dos Santos et al., 2008; Dutra et al., 2011; Gobel et al., 2011; Prat et al., 2005; Schulze-Topphoff et al., 2009) , suggesting that B 1 R inhibition may offer a novel anti-inflammatory strategy for the treatment of MS. Moreover, a report suggest that BK can modulate the cholinergic system, mainly in the airways (Barnes et al., 1998) . Herein, we demonstrated that deletion of B 1 R significantly prevented spatial reference memory impairments, reduction of ChAT mRNA levels in the hippocampus and prefrontal cortex, and blocked the increase of IL-17 and IFN-c mRNAs induced by EAE in the prefrontal cortex, lymph node and spleen.
Although B 2 R is commonly classified as a mediator of acute inflammatory responses, while B 1 R is thought to be involved in chronic inflammation (Costa-Neto et al., 2008) , one cannot rule out short-term and acute effects for B 1 R. The induction of B 1 R is associated with several processes, including: (i) production of inflammatory mediators, such as IL-1b, TNF-a, IL-2, and growth factors; (ii) stimulation of inflammatory cells; and (iii) activation of several intracellular signaling pathways, including NF-jB activation (Santos et al., 1999) . In addition, selective NF-jB blockers have been shown to be able to prevent B 1 R up-regulation, both in vitro (Sabourin et al., 2002) and in vivo (Passos et al., 2004) . Therefore, in cases of acute inflammation, over-production of pro-inflammatory cytokines may sustain the presence of active B 2 R as well as B 1 R. These data clearly demonstrate the relevance of different classes of proteins in the modulation of B 1 R up-regulation, and support the short-term effects of B 1 R. We have also reported that up-regulation of B 1 R in the hippocampus and prefrontal cortex, seems directly regulates neuroinflammatory responses and cognitive impairments in the motor pre-symptomatic phase of EAE. Thus, Fig. 7 . Potential mechanism by which B 1 R controls activation of CD4 + T cells into the CNS, leading to neuroinflammation, loss of cholinergic neurons and cognitive deficits during EAE. CD4 + T lymphocytes are primed in the peripheral lymphoid organs by dendritic cells (DCs) presenting myelin ) epitopes (1). After, CD4 + T cells enter into CNS by crossing the blood-brain barrier (BBB), mainly, in the choroid plexus (2), and within the subarachnoid space, Th17 and Th1 cells are re-activated by APCs expressing myelin epitopes (3). Finally, reactivated T cells, astrocytes and microglial cells (Dutra et al., 2013 ) (4) secrete neuroinflammatory soluble mediators that trigger demyelination (5), dead of cholinergic neurons (6), and consequently cognitive deficits. Spatial reference memory impairments occur before the onset of motor symptoms, which is directly associated with a decrease in ChAT expression in the brain, and appear to be mediated by kinin B 1 R. Moreover, activation of B 1 R could stimulate autoaggressive Th17 and Th1 cells to activate and release pro-inflammatory cytokines in the peripheral tissue, as well as within the CNS, consequently inducing cholinergic damage and cognitive impairments. Altogether, the modulation of this receptor may represent a novel therapeutic approach for MS. APC: antigen-presenting cell; Th cell: T helper lymphocyte; DABK: des-Arg 9 -BK; MOG: myelin oligodendrocytes glycoprotein; B 1 R: kinin B 1 receptor; B 2 R: kinin B 2 receptor; TCR: T cell receptor; MHC: major histocompatibility complex; CXCL1/KC: keratinocyte-derived chemokine, TNF-a: tumor necrosis factor-alpha; IL: interleukin; NOS2: nitric oxide synthase 2; COX-2: cyclooxygenase-2; IFN-c: interferon-gamma.
one could suppose that, after myelin antigen presentation to naïve lymphocytes T CD4 + , occurs B 1 R up-regulation, an effect that seems associate with differentiation into Th1 and Th17 cells, which migrate and accumulate within the gray/white matter structures, leading to neuroinflammation and consequently the loss of cholinergic neurons that is responsible for the onset of cognitive impairments (see scheme proposed in Fig. 7) .
Understanding of the mechanisms leading to cumulative cognitive deficits in patients with MS, and the further development of effective therapeutic strategies aimed at reducing disease progression, are major goals in MS research. Therefore, the characterization of early symptoms, plus identification of peptides/receptors associated with neuroinflammation, during the pre-symptomatic phase of MS, could give rise to temporal markers of the disease as well as open up fresh perspectives in the development of therapeutic approaches for MS. In summary, we described that spatial reference memory impairments occur before the onset of motor symptoms, and these effects are directly associated with a decrease in ChAT expression in the brain areas (hippocampus and prefrontal cortex) involved in acetylcholine control of memory acquisition and maintenance (Fig. 7) . Our data also show that the cognitive deficits, and cholinergic down-regulation, that appear in the mice prior to any overt motor deficits are strongly mediated by kinin receptors, mainly of the B 1 R subtype. Moreover, we demonstrated that the mechanisms involved in kinin receptor-mediated cognitive impairment during the pre-motor phase of EAE appear to be primarily associated with the ability of these peptides to stimulate autoaggressive Th17 and Th1 cell activation, proliferation and migration to the brain (Dutra et al., 2011) , release pro-inflammatory cytokines within the CNS, and consequently induced cholinergic damage and cognitive impairments (Fig. 7) . Therefore, the modulation of this receptor may represent a novel therapeutic approach for the management of MS.
